STTK Stock Up 105% after 6-Day Win Streak
Shattuck Labs (STTK) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 105% return. The company has gained about $108 Mil in value over the last 6 days, with its current market capitalization at about $103 Mil. The stock remains 66.1% above its value at the end of 2024. This compares with year-to-date returns of 10.7% for the S&P 500.
STTK is a clinical-stage biotechnology company developing therapeutics for cancer and autoimmune diseases in the United States.
Comparing STTK Stock Returns With The S&P 500
The following table summarizes the return for STTK stock vs. the S&P 500 index over different periods, including the current streak:
- Why The Dip In TEM Stock Is A Buying Window
- Can Pfizer Stock Outrun A $17B Revenue Void?
- Chevron Earnings: Upstream Strength Overcomes Downstream Accounting Headwinds
- What Is Happening With Arista Networks Stock?
- How Much Upside Can V Stock Deliver?
- Kyndryl Stock: Strong Cash Flow Poised for a Re-Rating?
| Return Period | STTK | S&P 500 |
|---|---|---|
| 1D | 6.9% | 0.3% |
| 6D (Current Streak) | 104.9% | 0.8% |
| 1M (21D) | 165.8% | 1.9% |
| 3M (63D) | 68.9% | 8.4% |
| YTD 2025 | 66.1% | 10.7% |
| 2024 | -83.0% | 23.3% |
| 2023 | 210.0% | 24.2% |
| 2022 | -73.0% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 39 S&P constituents with 3 days or more of consecutive gains and 57 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 12 | 47 |
| 4D | 10 | 6 |
| 5D | 13 | 2 |
| 6D | 3 | 1 |
| 7D or more | 1 | 1 |
| Total >=3 D | 39 | 57 |
Key Financials for Shattuck Labs (STTK)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $1.7 Mil | $5.7 Mil |
| Operating Income | $-92.0 Mil | $-80.6 Mil |
| Net Income | $-87.3 Mil | $-75.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-14.4 Mil | $-13.0 Mil |
| Net Income | $-13.7 Mil | $-12.5 Mil |
While STTK stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.